{"id":"NCT02752906","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine","officialTitle":"Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-15","primaryCompletion":"2016-12-19","completion":"2016-12-19","firstPosted":"2016-04-27","resultsPosted":"2020-06-05","lastUpdate":"2022-04-05"},"enrollment":810,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Meningitis","Meningococcal Meningitis","Meningococcal Infections"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine","otherNames":["MenACYW Conjugate vaccine"]},{"type":"BIOLOGICAL","name":"Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine","otherNames":["Menactra®"]}],"arms":[{"label":"MenACYW Conjugate Vaccine","type":"EXPERIMENTAL"},{"label":"Menactra®","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of the study was to describe the safety and antibody response to booster administration with Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine in participants who received their first quadrivalent meningococcal Conjugate vaccine dose in the past 4-10 years.\n\nPrimary Objective:\n\n* To demonstrate the non-inferiority of the vaccine seroresponse of meningococcal serogroups A, C, Y, and W following the administration of a booster dose of MenACYW Conjugate vaccine compared to those observed following the administration of a booster dose of Menactra® in participants who were first vaccinated with 1 dose of a quadrivalent meningococcal vaccine 4 to 10 years before the booster dose.\n\nSecondary Objectives:\n\n* To evaluate the vaccine seroresponse of meningococcal serogroups A, C, Y, and W measured using human serum bactericidal assay (hSBA) in serum specimens collected 6 days after vaccination in a subset of 120 participants.\n* To evaluate the antibody responses (geometric mean titers) to serogroups A, C, Y, and W measured using hSBA on Day 0 (pre-vaccination) and Day 30 after vaccination.\n\nObservational Objectives:\n\n* To describe the antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA assessed at Day 0, Day 6, and Day 30 days after vaccination.\n* To describe the antibody responses to the meningococcal serogroups A, C, Y, and W before and 30 days after vaccination with MenACYW Conjugate vaccine or Menactra® measured by rabbit serum bactericidal assay (rSBA) in a subset of participants.\n* To describe the safety profile of MenACYW Conjugate vaccine compared to that of a licensed Menactra® after booster vaccination.","primaryOutcome":{"measure":"Percentage of Participants With Seroresponse to Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine","timeFrame":"Day 30 (post-vaccination)","effectByArm":[{"arm":"MenACYW Conjugate Vaccine","deltaMin":92.2,"sd":null},{"arm":"Menactra ®","deltaMin":87.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":19},"locations":{"siteCount":30,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["32209015"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":402},"commonTop":["Injection Site Pain","Myalgia","Headache","Malaise"]}}